Insider Trading Alert - LGND, NSP And FSLR Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.
Yesterday, March 3, 2015, 111 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $58.00 to $21,695,559.83.
Highlighted Stocks Traded by Insiders:
Ligand Pharmaceuticals (LGND) - FREE Research Report
Herman Melanie J, who is Director of Accounting at Ligand Pharmaceuticals, sold 535 shares at $60.69 on March 3, 2015. Following this transaction, the Director of Accounting owned 2,986 shares meaning that the stake was reduced by 15.19% with the 535-share transaction.
The shares most recently traded at $67.70, up $7.01, or 10.35% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:
- 4-Week # shares bought: 275
- 4-Week # shares sold: 510
- 12-Week # shares bought: 275
- 12-Week # shares sold: 510
- 24-Week # shares bought: 2,360
- 24-Week # shares sold: 510
The average volume for Ligand Pharmaceuticals has been 278,300 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 24.88% year-to-date as of the close of trading on Tuesday.
Ligand Pharmaceuticals Incorporated, a biotechnology company, acquires and develops royalty revenue generating assets in the United States. The company has a P/E ratio of 113.5. Currently, there are 3 analysts who rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on LGND - FREE
rates Ligand Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
Ligand Pharmaceuticals Ratings Report
from
now.
Insperity (NSP) - FREE Research Report
Arizpe Arthur A, who is EVP of Client Services & COO at Insperity, sold 5,000 shares at $53.00 on March 3, 2015. Following this transaction, the EVP of Client Services & COO owned 113,173 shares meaning that the stake was reduced by 4.23% with the 5,000-share transaction.
The shares most recently traded at $53.20, up $0.20, or 0.38% since the insider transaction. Historical insider transactions for Insperity go as follows:
- 4-Week # shares sold: 61,254
- 12-Week # shares sold: 61,254
- 24-Week # shares sold: 64,754
The average volume for Insperity has been 325,400 shares per day over the past 30 days. Insperity has a market cap of $1.3 billion and is part of the services sector and diversified services industry. Shares are up 56.42% year-to-date as of the close of trading on Tuesday.
Insperity, Inc. provides an array of human resources (HR) and business solutions to enhance business performance for small and medium-sized businesses in the United States. The stock currently has a dividend yield of 1.44%. The company has a P/E ratio of 50.4. Currently, there are 2 analysts who rate Insperity a buy, no analysts rate it a sell, and 3 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on NSP - FREE
rates Insperity as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full
from
now.
First Solar (FSLR) - FREE Research Report
Widmar Mark R, who is Chief Financial Officer/CAO at First Solar, sold 10,000 shares at $60.00 on March 3, 2015. Following this transaction, the Chief Financial Officer/CAO owned 24,095 shares meaning that the stake was reduced by 29.33% with the 10,000-share transaction.
The shares most recently traded at $60.80, up $0.80, or 1.32% since the insider transaction. Historical insider transactions for First Solar go as follows:
- 4-Week # shares sold: 45,958
- 12-Week # shares bought: 1,000
- 12-Week # shares sold: 45,958
- 24-Week # shares bought: 1,000
- 24-Week # shares sold: 45,958
The average volume for First Solar has been 3.4 million shares per day over the past 30 days. First Solar has a market cap of $6.1 billion and is part of the technology sector and electronics industry. Shares are up 36.09% year-to-date as of the close of trading on Tuesday.
First Solar, Inc. provides solar energy solutions worldwide. The company operates through two segments, Components and Systems. The company has a P/E ratio of 15.6. Currently, there are 7 analysts who rate First Solar a buy, no analysts rate it a sell, and 8 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on FSLR - FREE
rates First Solar as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, growth in earnings per share and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
from
now.
null